An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents



Status:Completed
Conditions:Podiatry
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:Any
Updated:1/24/2018
Start Date:October 22, 2015
End Date:July 27, 2017

Use our guide to learn which trials are right for you!

An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months

This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5%
topical solution in treating distal subungual onychomycosis (a fungal infection) of the
toenail in children and adolescents (ages 6 to 16 years).

Following confirmation of eligibility, including laboratory evidence of a fungal organism in
the toenail, tavaborole topical solution was applied once daily to all affected toenails for
a 48-week treatment period.

Clinical assessment of the extent of infection and safety assessments were performed
periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after
stopping the treatment).

A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small
area of surrounding skin during the first 28 days. These subjects had blood samples analyzed
to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical
solution in children and adolescents.

This was an open-label study to evaluate the safety, tolerability, and pharmacokinetics of
tavaborole 5% topical solution in treating distal subungual onychomycosis (DSO) of the
toenail in pediatric subjects aged 6 to 16 years and 11 months. An eligible subject had a
target great toenail (TGT) with at least 20% involvement, with a positive potassium hydroxide
(KOH) wet mount and positive fungal culture for T. rubrum or T. mentagrophytes.

Eligible subjects applied tavaborole 5% topical solution, once daily to all affected toenails
(the TGT as well as all other toenails having the clinical characteristics of onychomycosis)
throughout the 48 week treatment period.

Subjects were evaluated at Screening, Baseline (Day 1), and at Weeks 2, 4, 8, 16, 24, 32, 40,
48, and 52. Each evaluation included a clinical assessment of the AEs and local tolerability
evaluation.

Additional procedures were performed as follows:

- Mycology sampling at Screening, Week 24, and Week 52/early termination (ET);

- Clinical disease severity of the TGT at Screening, Week 24, and Week 52/ET;

- Safety laboratory testing at Baseline, Week 24, and Week 52/ET;

In this study, there was a PK subgroup of evaluable subjects aged 12 to 16 years and 11
months studied under maximal use conditions. Subjects in this maximal use subgroup applied
the study drug on all 10 toenails, including up to 2 mm of the surrounding skin, for 28 days.
On Day 15, a predose PK sample was collected to assess steady state trough level. On Day 29,
the study drug application was done at the study site, and PK samples were collected prior to
dosing, as well as 4, 6, 8, and 24 hours postdose on Days 29 to 30.

Inclusion Criteria:

- males or females, ages >/= 6 years and
- clinical diagnosis of distal subungual onychomycosis affecting at least 20% of one of
the great toenails (target nail); and with positive KOH and positive culture for T.
rubrum or T. mentagrophytes from either great toenail

Exclusion Criteria:

- the target toenail has proximal subungual onychomycosis, onychomycosis involving the
nail lunula, superficial white onychomycosis, dermatophytoma, exclusively lateral
disease, or yellow or brown spikes, or has co-infection with certain fungi or molds

- anatomic abnormalities of the toes or toenail

- current or past history of chronic moccasin-type tinea pedis

- current or past history of psoriasis or lichen planus

- history of significant chronic fungal disease (other than onychomycosis)

- diabetes

- immunodeficiency
We found this trial at
12
sites
3800 Reservoir Road Northwest
Washington, District of Columbia 20016
?
mi
from
Washington,
Click here to add this to my saved trials
450 Clarkson Avenue
Brooklyn, New York 11203
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Burke, Virginia 22015
?
mi
from
Burke, VA
Click here to add this to my saved trials
Gresham, Oregon 97030
?
mi
from
Gresham, OR
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Madera, California 93637
?
mi
from
Madera, CA
Click here to add this to my saved trials
New York, New York 10155
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Portland, Oregon 97210
?
mi
from
Portland, OR
Click here to add this to my saved trials
San Antonio, Texas 78218
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
South Miami, Florida 33143
?
mi
from
South Miami, FL
Click here to add this to my saved trials
West Jordan, Utah 84088
?
mi
from
West Jordan, UT
Click here to add this to my saved trials